Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
United Therapeutics (UTHR) reported insider transactions by a Director and Chairperson & CEO. On 11/06/2025 and 11/07/2025, the reporting person exercised 4,000 stock options each day at $120.26 per share and sold a total of 8,000 shares in multiple trades at weighted average prices between $446.00 and $452.21, pursuant to a pre‑arranged Rule 10b5‑1 trading plan.
Following the transactions, direct holdings were 130 shares. Indirect holdings included 166 shares by spouse and family trust positions of 324,518, 258,117, 45,596, and 15,962 shares. Derivative holdings showed 114,000 stock options remaining after the reported exercises.
The 10b5‑1 plan, entered on May 2, 2025, continues until the earlier of exhaustion of a tranche of 294,000 options expiring March 15, 2026, or December 31, 2025.
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO. On Nov 4, 2025 and Nov 5, 2025, the insider exercised 4,000 stock options each day at an exercise price of $120.26 and sold 4,000 shares each day at weighted average prices ranging from approximately $432.53 to $442.262. These trades were made under a Rule 10b5-1 trading plan entered on May 2, 2025, which continues until the earlier of the exhaustion of a 294,000-option tranche expiring March 15, 2026 or December 31, 2025.
Following the reported transactions, direct holdings were 130 shares. The filing also lists additional indirect holdings by spouse and family trusts.
United Therapeutics (UTHR) disclosed that its CFO and Treasurer exercised 21,000 stock options at $146.03 and sold the resulting shares in multiple trades on November 4, 2025 under a Rule 10b5-1 trading plan entered on August 5, 2025.
The sales were executed in blocks at weighted average prices ranging from $432.0874 to $439.5102, covering all 21,000 shares acquired upon exercise. After these transactions, the reporting person directly owned 8,118 shares of common stock.
United Therapeutics (UTHR) Chairperson & CEO reported option exercises and open‑market sales under a pre‑arranged Rule 10b5‑1 plan. On 10/31/2025 and 11/03/2025, the insider exercised 4,000 stock options each day at an exercise price of $120.26 per share (8,000 total), then sold 4,000 shares each day in multiple trades.
Weighted average sale prices on 10/31/2025 included $447.826, $449.835, and $451.4864. On 11/03/2025, sales occurred at weighted averages of $433.7769, $434.3311, $438.624, $441.39, and $443.01. Following the transactions, direct holdings were 130 shares, with additional indirect holdings of 166 (by spouse) and trusts holding 324,518, 258,117, 45,596, and 15,962 shares. Derivative securities beneficially owned were 130,000 options after the 11/03 exercise. The trading plan, entered on May 2, 2025, continues until the earlier of exhaustion of a tranche of 294,000 options expiring March 15, 2026, or December 31, 2025.
United Therapeutics (UTHR) reported insider activity by its President and COO. On 11/03/2025, the reporting person exercised 14,625 stock options at $135.42 and 7,875 options at $146.03, then sold the resulting shares in multiple tranches. The sales were effected at weighted average prices that included $417.4965, $432.5476, and up to $441.9446, with individual trade ranges disclosed between $432.02 and $442.31.
The filing states these transactions were executed under a Rule 10b5‑1 trading plan entered on June 3, 2025. The options were exercised and shares sold through trusts for which the reporting person has investment and voting power as described, including a family trust. Following the transactions, the form shows 41,250 and 10,500 derivative securities (options) beneficially owned, as applicable to the noted trusts.
United Therapeutics (UTHR) disclosed a routine insider update. A company director reported a Form 4 transaction coded “G” involving 450 shares on 11/03/2025 at $0.00 per share. Following this activity, the director’s beneficial ownership stands at 4,190 shares, held directly.
United Therapeutics (UTHR) Chairperson & CEO reported Form 4 transactions under a pre-arranged Rule 10b5-1 plan. On 10/29/2025, she exercised 4,000 options at $120.26 and sold 1,100 shares at $433.31, 2,000 at $435.24, and 900 at $439.99. On 10/30/2025, she exercised another 4,000 options at $120.26 and sold 1,500 at $447.135, 541 at $448.425, 1,459 at a weighted average of $450.2338, and 500 at $451.29.
The filing shows 130 shares held directly after the reported trades and 138,000 stock options remaining. Indirect holdings include 166 shares by spouse and shares held across family trusts. The 10b5‑1 plan, entered on May 2, 2025, continues until the earlier of a 294,000-option tranche’s exhaustion (expiring March 15, 2026) or December 31, 2025.
United Therapeutics (UTHR) reported an insider transaction by its EVP & General Counsel. On 10/30/2025, the officer exercised 11,000 stock options at $135.42 and sold the resulting 11,000 shares in multiple trades under a pre‑arranged Rule 10b5‑1 plan entered on December 24, 2024. Weighted average sale prices for the blocks ranged from $447.3438 to $454.1471. Following these transactions, the officer beneficially owned 36,781 shares directly and 22,000 derivative securities (stock options) as reported.
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO under a Rule 10b5-1 plan. On 10/27/2025 and 10/28/2025, the insider exercised 4,000 stock options each day at an exercise price of $120.26 per share and sold the resulting shares in open-market trades.
Sales on 10/27 were 1,000 shares at $411.9545, 1,814 at $414.4191, and 1,186 at $420.2887. Sales on 10/28 were 1,991 at $413.5798, 509 at $415.02, and 1,500 at $417.915. Following these transactions, direct holdings were 130 shares. Indirect holdings include 166 by spouse, 324,518 and 257,117 by family trusts, and 45,596 and 15,962 via spouse-related trusts.
The filing states the 10b5-1 plan was entered on May 2, 2025 and will continue until the earlier of exhaustion of a tranche of 294,000 options expiring March 15, 2026 or December 31, 2025.
United Therapeutics Corporation furnished a Form 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The company stated this information shall not be deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings, except as specifically referenced.